Drug Monitoring and Toxicology: A Procedure for the Monitoring of Levetiracetam and Zonisamide by HPLC-UV | Zendy

JoEtta M. Juenke | Zendy; Paul I. Brown | Zendy; Francis M. Urry | Zendy; Gwendolyn A. McMillin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug Monitoring and Toxicology: A Procedure for the Monitoring of Levetiracetam and Zonisamide by HPLC-UV

Author(s) -

JoEtta M. Juenke,

Paul I. Brown,

Francis M. Urry,

Gwendolyn A. McMillin

Publication year - 2006

Publication title -

journal of analytical toxicology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.161

H-Index - 76

eISSN - 1945-2403

pISSN - 0146-4760

DOI - 10.1093/jat/30.1.27

Subject(s) - levetiracetam , zonisamide , chromatography , high performance liquid chromatography , therapeutic drug monitoring , detection limit , chemistry , pharmacology , forensic toxicology , drug , epilepsy , medicine , topiramate , psychiatry

This article describes a rapid isocratic high-performance liquid chromatographic (HPLC) method for the simultaneous measurement of the anticonvulsants levetiracetam and zonisamide. Monitoring these drugs is important for detecting potentially toxic concentrations, particularly in patients with renal impairment, but no commercial assays are currently available. Following a liquid-liquid extraction, levetiracetam (5-150 microg/mL) and zonisamide (5-80 microg/mL) are quantitated by HPLC-UV. The assay's limit of quantitation, linearity, imprecision, and accuracy adequately cover the therapeutic range of these drugs. The assay should be attractive to clinical laboratories because the run time for quantification of both drugs is approximately 5 min per sample, and no interferences are currently known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research